COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome

Ilana Levy, Avital Lavi, Eran Zimran, Sigal Grisariu, Shlomzion Aumann, Gilad Itchaki, Tamar Berger, Pia Raanani, Reut Harel, Ariel Aviv, Noa Lavi, Tsila Zuckerman, Lev Shvidel, Osnat Jarchowsky, Martin Ellis, Katrin Herzog Tzarfati, Maya Koren-Michowitz, Yehonatan Sherf, Itai Levi, Orit SoferOfer Shpilberg, Nagib Dally, Celia Suriu, Andrei Braester, Sharon Ben Barouch, Merav Leiba, Daniela Goldstein, Nadav Sarid, Shay Yeganeh, Jabour Halloun, Moshe Mittelman, Tamar Tadmor

    Research output: Contribution to journalArticlepeer-review

    24 Scopus citations

    Abstract

    This national Israeli multicenter retrospective study aimed to characterize the clinical course of COVID-19 infection among patients with hematological malignancies, with special emphasis on treatment efficacy and outcome. Clinical and laboratory data from haemato-oncological patients diagnosed with COVID-19 from 16 medical centers were centrally reported. Multivariate regression analyses were used to determine variables associated with severe disease, hospitalization, and mortality. In total, 313 patients were included: 103 (35.7%) developed severe/critical respiratory infection, 178 (61.4%) were hospitalized, and 60 (20.0%) died. Age > 70 years was associated with severe/critical disease (p = 0.036) and mortality (p = 0.023), hypertension with severe/critical disease (p = 0.046) and hospitalization (p = 0.001), active haemato-oncological treatment with hospitalization (p = 0.009), and remdesivir treatment was associated with decreased mortality (p = 0.021). Convalescent plasma, enoxaparin, and corticosteroids resulted in no clinical benefit. In conclusion, COVID-19 infection seems particularly severe in patients with hematological malignancies, and of all examined therapies, remdesivir appears to be the most effective.

    Original languageEnglish
    Pages (from-to)3384-3393
    Number of pages10
    JournalLeukemia and Lymphoma
    Volume62
    Issue number14
    DOIs
    StatePublished - 1 Jan 2021

    Keywords

    • COVID-19
    • Haemato-oncological
    • multicenter
    • retrospective

    ASJC Scopus subject areas

    • Hematology
    • Oncology
    • Cancer Research

    Fingerprint

    Dive into the research topics of 'COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome'. Together they form a unique fingerprint.

    Cite this